The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects

Journal of Clinical Pharmacology

Volumn 45, Issue 12, 2005, Pages 1400-1406

  Sogaard B ^a   Mengel, H ^a   Rao, N ^b   Larsen, F ^a  

^a H LUNDBECK A S   (Denmark)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Bioequivalence; Citalopram; Cross over; Enantiomer; Escitalopram; Healthy volunteers; Multiple dose; Pharmacokinetics; Single dose; Tolerability

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DINORCITALOPRAM; DRUG METABOLITE; ESCITALOPRAM; NORCITALOPRAM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; ENANTIOMER; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; GENOTYPE; HEADACHE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOLOGICAL AVAILABILITY; CITALOPRAM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; SEROTONIN UPTAKE INHIBITORS;

EID: 27844526619     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280860     Document Type: Article

References (14)

1. Chen F, Larsen MB, Sánchez C, Wiborg O. The S-enantiomerof R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism: comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005;15:193-198.
2. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs. 1997;8:410-431.
3. Sánchez C, Bøgesø KP, Ebert B, Reines EH, Bræstrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl). 2004;174:163-176.
4. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17:343-362.
5. Bech P, Tanghøj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol. 2004;7:283-290.
6. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract. 2005;59:268-275.
7. von Moltke LL, Greenblatt DJ, Giancarlo GM, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Disp. 2001;29:1102-1109.
8. Herrlin K, Yasui-Furukori N, Tybring G, Widén J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol. 2003;56:415-421.
9. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother. 1995;6:287-295.
10. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003;25:1200-1210.
11. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram. Br J Clin Pharmacol. 2005;60:287-290.
12. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F. Steady state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality. 1997;9:686-692.
13. Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, Sidhu J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol. 1998;54:237-242.
14. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88:157-160.